Company Overview and News

0
Heron awards transport contract for Woodlawn zinc-copper project

7h australianmining.com.au
Heron Resources has awarded the road and rail logistics services contract for its Woodlawn zinc-copper project in New South Wales to local supplier Crawfords Freightlines.
HRR HER

0
Heron Awards Concentrate Logistics Contract

8h globenewswire
Sydney, Australia, June 21, 2018 (GLOBE NEWSWIRE) -- Heron Resources Limited (ASX:HRR, “Heron” or the “Company”) is pleased to announce the award of a sigificant transportation services contract with Crawfords Freightlines Pty Ltd (“Crawfords”) for its wholly owned Woodlawn Zinc-Copper Project in New South Wales, Australia.
HRR HER

0
Heron Locks in Electricity Supply Contract to Power Woodlawn Mine

2018-06-18 globenewswire
Sydney, Australia, June 18, 2018 (GLOBE NEWSWIRE) -- Heron Resources Limited (ASX:HRR, “Heron” or the “Company”) is pleased to announce it has signed an electricity supply contract with a major electricity retailer to power the Woodlawn Mine through the commissioning phase and into production in early 2019.
HRR HER

4
Heron Resources Files Application to Cease to be a Reporting Issuer in Canada

2018-06-11 globenewswire
SYDNEY, Australia, June 11, 2018 (GLOBE NEWSWIRE) -- Heron Resources Limited (“Heron” or the “Company”) (ASX:HRR) announces that the ordinary shares of Heron were voluntarily delisted from the Toronto Stock Exchange on March 29, 2018. Since that time, the Company has remained a reporting issuer in Ontario, Canada.
HRR MALRY MALRF MIN HER

0
Heron’s Drilling of G2 & Lisa Lenses at Woodlawn Deliver High Grade Assays

2018-06-04 globenewswire
Sydney, Australia, June 04, 2018 (GLOBE NEWSWIRE) -- Heron Resources Limited (ASX:HRR “Heron” or the “Company”) is pleased to report that it has received assays for the recently intersected base-metal mineralisation at its wholly-owned Woodlawn Zinc-Copper Project, located 250km south-west of Sydney, New South Wales, Australia. The intercepts at both the G2 and Lisa Lens positions extend the known limits of the mineralisation in these areas and is expected to provide additional early-stage production for the operation.
HRR HER

0
Heron Completes Draw-Down of First Tranche of US$20M Debt; Project More Than 50% Complete

2018-05-31 globenewswire
Sydney, Australia, May 31, 2018 (GLOBE NEWSWIRE) -- Heron Resources Limited (ASX:HRR, “Heron” or the “Company”) is pleased to announce it has completed the draw-down of the first tranche of US$20M of debt from Orion Mine Finance. As announced to the market on 30 June 2017, the total debt provided by Orion Mine Finance is US$60M; the remaining US$40M remains undrawn and is available to Heron.
HRR HER

4
Heron Awards Key Tailings Mining Contracts

2018-05-22 globenewswire
Heron Resources Limited (ASX:HRR, “Heron” or the “Company”) is pleased to announce the award of two contracts relating to the provision of equipment supply and mining services for the reclamation of tailings for reprocessing at its wholly owned Woodlawn Zinc-Copper Project in New South Wales, Australia, which is currently under construction and due to commence commissioning at the end of 2018.
HRR MALRY MALRF MIN HER

0
Heron awards Woodlawn contracts

2018-05-21 australianmining.com.au
Heron Resources has awarded two key contracts for the Woodlawn zinc-copper project in New South Wales.
HRR HER

0
Heron’s G2 Lens Delivers Strong Metallurgical Results

2018-05-08 globenewswire
Sydney, Australia, May 08, 2018 (GLOBE NEWSWIRE) -- Heron Resources Limited (ASX:HRR, “Heron” or the “Company”) is pleased to report results from a metallurgical testwork program undertaken on the shallow G2 Lens at its wholly owned Woodlawn Zinc-Copper Project in New South Wales, Australia. The G2 Lens represents the first mineralisation to be accessed in the underground operation and is not currently reported within the operations Ore Reserves.
HRR HER

0
Heron Resources (HRLDF) Presents At 121 Mining Investment - Slideshow

2018-04-23 seekingalpha
The following slide deck was published by Heron Resources Limited HRR in conjunction with this event.
HRR HRLDF HER

0
Heron’s Peelwood Project - EM Drill Targets Identified

2018-04-23 globenewswire
Sydney, Australia, April 23, 2018 (GLOBE NEWSWIRE) -- Heron Resources Limited (ASX:HRR, “Heron” or the “Company”) is pleased to report that a number of drill ready EM anomalies have been identified at its wholly owned Peelwood base metal project located 105 km north of the Company’s Woodlawn Zinc-Copper Project in New South Wales, Australia.
HRR HER

0
Heron’s Drilling Delivers Massive Sulphide Intercepts at G2 and Lisa Lenses

2018-04-19 globenewswire
Sydney, New South Wales, April 19, 2018 (GLOBE NEWSWIRE) -- Heron Resources Limited (ASX:HRR “Heron” or the “Company”) is pleased to advise that it has intersected significant base-metal sulphide mineralisation at its wholly-owned Woodlawn Zinc-Copper Project, located 250km south-west of Sydney, New South Wales, Australia. The intercepts at both the G2 and Lisa Lens positions extend the limits of the mineralisation in these areas and will provide additional early stage production for the operation.
HRR HER

0
Zinc Is Preparing To Turn Higher

2018-04-17 seekingalpha
Zinc is shaking out the weak players before what is likely going to be a dramatic move higher.
HRR HRLDF NCRE VEDL TREVF HER VEDL

3
Top 5 Nickel Miners To Consider Before The Nickel Boom

2018-03-28 seekingalpha
Nickel is likely to do well in 2018 to 2020 as it recovers from a severe bear market.
RNX RNX.WT HRR RNKLF LNZCF HER ERA

13
Heron’s Woodlawn Project on Track for Year-end Commissioning

2018-03-28 globenewswire
Sydney, Australia, March 28, 2018 (GLOBE NEWSWIRE) -- Heron Resources Limited (ASX:HRR TSX:HER, “Heron” or the “Company”) is pleased to provide the following construction update on the Company’s Woodlawn Zinc-Copper Project in New South Wales, Australia. Significant progress has been made on site, most recently with the commencement of process plant foundations and first deliveries of process plant equipment.
HRR TCKRF HER TECK

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

Silicon Investor Message Boards

This table lists all message boards related to TSX:HER / Heron Resources Limited on message board site Silicon Investor.

Buy and Sell Signals, and Other Market Perspectives Catch_As_Catch_Can Charts and Other Stuff
Stock Watcheru0027s Thread / Pix of the Week (POW) Nanoviricides - The Other Board
Trillium Therapeutics vitamins herbs supplements longevity and aging
Socialized Education - Is there abetter way? Where the GITu0027s are going
Test Your HTML Here Before You Post It! Sorrento Therapeutics Inc